Drug Profile
Research programme: immune cell therapeutics - Adicet Bio/Regeneron
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Adicet Bio; Regeneron Pharmaceuticals
- Developer Regeneron Pharmaceuticals
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 06 May 2019 Research programme: immune cell therapeutics is available for licensing as of 06 May 2019. http://kenes-exhibitions.com/biomed/wp-content/uploads/175_Adicetbio.pdf